Hormonal
Obesity significantly increases the risk of cardiovascular diseases (CVDs), including hypertension, coronary artery disease, heart failure, and arrhythmias, through mechanisms involving inflammation, endothelial dysfunction, and cardiac structural changes.
If you have obesity, you are at a significantly higher risk for heart disease, high blood pressure, and heart failure. This risk is driven by inflammation and structural changes in the heart. Weight loss through lifestyle changes is crucial for managing these risks. Regular screening for blood pressure, cholesterol, and heart function is recommended.
Obesity directly fosters the onset of various cardiovascular risk factors, such as dyslipidemia, T2DM, hypertension, and sleep disorders... obesity increases the risk of CVDs. Notably, obesity correlates with an increased occurrence of hypertension, coronary artery disease, heart failure, and arrhythmia.
Why this rating
Supported by multiple prospective cohort studies, meta-analyses, and registry data cited in the review.
Source
Navigating obesity: A comprehensive review of epidemiology, pathophysiology, complications and management strategies
Ning Xiao et al. · The Innovation Medicine · 2024
DOI 10.59717/j.xinn-med.2024.100090
More from this paper
- Lifestyle interventions (dietary changes and physical activity) are the foundational and preferred first-line treatment for obesity management, although they are difficult for many patients to maintain long-term.Strong
- Obesity is a major risk factor for various cancers, including endometrial, ovarian, prostate, colorectal, pancreatic, liver, gallbladder, kidney, thyroid, and meningioma, as well as hematological malignancies like multiple myeloma and leukemia.Strong
- Obesity is a significant risk factor for respiratory diseases, including obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), and asthma, primarily due to mechanical effects on lung volume and airway collapse.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →